申请人:Bearsden Bearsden Bio, Inc.
公开号:US05716956A1
公开(公告)日:1998-02-10
Substituted dihydrophthalazine compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.
提供了替代二氢邻苯二酮的组合物,其作为非NMDA离子型兴奋性氨基酸(EAA)受体拮抗剂具有活性。这些组合物可用于治疗与离子型EAA受体的非NMDA亚型过度激活相关的疾病。这些化合物进一步可用作测试试剂,以识别和表征其他化合物,用于治疗这些疾病。这些化合物在治疗上可用作镇静剂或用于治疗脑神经药理学疾病,如中风、缺血和癫痫。这些组合物可以与适当的载体结合,用于口服或静脉注射给药。这些化合物可以口服或静脉注射,用于治疗与非NMDA EEA受体功能相关的各种疾病。